Pfizer has entered into an exclusive collaboration and license agreement with YaoPharma for the development and commercialization of YP05002, a GLP-1 receptor agonist targeting chronic weight management.

Target Information

Pfizer Inc., a globally recognized biopharmaceutical company, has initiated an exclusive collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical Group. This partnership focuses on the development of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist that is currently undergoing Phase 1 clinical trials aimed at chronic weight management. Through this agreement, Pfizer aims to leverage its expertise and resources to advance YP05002, which complements its existing portfolio of innovative treatments targeting obesity and related diseases.

Chris Boshoff, M.D., Ph.D., Chief Scientific Officer at Pfizer, has expressed optimism about the collaboration, highlighting that cardiometabolic research is a strategic priority for the company with significant potential for business growth. Under the terms of this agreement, YaoPharma is responsible for completing the ongoing Phase 1 clinical trial and has granted Pfizer an exclusive license to further develop, manufacture, and commercialize YP05002 across global markets.

Industry Overview in China

The healthcare industry in China has seen rapid growth in recent years, largely driven by increasing consumer demand, government investment, and healthcare reforms. The Chinese government has made significant strides to improve access to heal